AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Research
The volume and pace of cancer research, from preclinical studies to clinical trials and FDA approvals, can make it challenging to stay informed. This section highlights the latest developments and translates complex scientific concepts into clear, accessible insights for both healthcare professionals and the broader public.
Building CAR-T Access Where Patients Live: Lessons from a Hybrid Community-Academic Cancer Center
By Swathi Namburi, MD
Dr. Swathi Namburi discusses how hybrid community-academic cancer centers can expand CAR-T access through clinical trials, telehealth, hub-and-spoke care models, and community-based delivery.
Building CAR-T Access Where Patients Live: Lessons from a Hybrid Community-Academic Cancer Center
By Swathi Namburi, MD
Dr. Swathi Namburi discusses how hybrid community-academic cancer centers can expand CAR-T access through clinical trials, telehealth, hub-and-spoke care models, and community-based delivery.
Building CAR-T Access Where Patients Live: Lessons from a Hybrid Community-Academic Cancer Center
By Swathi Namburi, MD
Dr. Swathi Namburi discusses how hybrid community-academic cancer centers can expand CAR-T access through clinical trials, telehealth, hub-and-spoke care models, and community-based delivery.
Interpreting Bladder Cancer Abstracts at GU ASCO 2026 for Real-World Practice
By Jason Brown, MD, PhD
Expert commentary from a genitourinary oncologist on top research from ASCO Genitourinary Cancers Symposium
Interpreting Bladder Cancer Abstracts at GU ASCO 2026 for Real-World Practice
By Jason Brown, MD, PhD
Expert commentary from a genitourinary oncologist on top research from ASCO Genitourinary Cancers Symposium
Interpreting Bladder Cancer Abstracts at GU ASCO 2026 for Real-World Practice
By Jason Brown, MD, PhD
Expert commentary from a genitourinary oncologist on top research from ASCO Genitourinary Cancers Symposium
Key ASH 2025 Updates in Non-Hodgkin Lymphoma
By Madiha Iqbal, MD
Key ASH 2025 updates in non-Hodgkin lymphoma highlight CAR-T durability, bispecific antibody breakthroughs, and new FDA-approved therapies reshaping treatment for DLBCL and follicular lymphoma.
Key ASH 2025 Updates in Non-Hodgkin Lymphoma
By Madiha Iqbal, MD
Key ASH 2025 updates in non-Hodgkin lymphoma highlight CAR-T durability, bispecific antibody breakthroughs, and new FDA-approved therapies reshaping treatment for DLBCL and follicular lymphoma.
Key ASH 2025 Updates in Non-Hodgkin Lymphoma
By Madiha Iqbal, MD
Key ASH 2025 updates in non-Hodgkin lymphoma highlight CAR-T durability, bispecific antibody breakthroughs, and new FDA-approved therapies reshaping treatment for DLBCL and follicular lymphoma.
Frontline Treatment of Hodgkin Lymphoma in 2026: A New Standard Emerges
By Hun Ju Lee, MD
Expert analysis of how SWOG S1826, nivolumab-based regimens, PET-adapted therapy, and immunotherapy combinations are redefining frontline treatment for classical Hodgkin lymphoma in 2026.
Frontline Treatment of Hodgkin Lymphoma in 2026: A New Standard Emerges
By Hun Ju Lee, MD
Expert analysis of how SWOG S1826, nivolumab-based regimens, PET-adapted therapy, and immunotherapy combinations are redefining frontline treatment for classical Hodgkin lymphoma in 2026.
Frontline Treatment of Hodgkin Lymphoma in 2026: A New Standard Emerges
By Hun Ju Lee, MD
Expert analysis of how SWOG S1826, nivolumab-based regimens, PET-adapted therapy, and immunotherapy combinations are redefining frontline treatment for classical Hodgkin lymphoma in 2026.
Frontline EGFR-Mutant NSCLC: Navigating an Era of Combination Therapy
By Angel Qin, MD
New frontline therapies are transforming EGFR-mutant NSCLC care. Learn how MARIPOSA, FLAURA2, and emerging biomarker-driven strategies are reshaping treatment selection and survival outcomes.
Frontline EGFR-Mutant NSCLC: Navigating an Era of Combination Therapy
By Angel Qin, MD
New frontline therapies are transforming EGFR-mutant NSCLC care. Learn how MARIPOSA, FLAURA2, and emerging biomarker-driven strategies are reshaping treatment selection and survival outcomes.
Frontline EGFR-Mutant NSCLC: Navigating an Era of Combination Therapy
By Angel Qin, MD
New frontline therapies are transforming EGFR-mutant NSCLC care. Learn how MARIPOSA, FLAURA2, and emerging biomarker-driven strategies are reshaping treatment selection and survival outcomes.
LGBTQ+ Cancer Disparities, Data Gaps, and the Clinical Stakes of Invisibility
By Mandi L. Pratt-Chapman, PhD
Expert commentary from Mandi L. Pratt-Chapman, PhD, on LGBTQ+ cancer disparities, SOGI data gaps, clinical trial inclusion, and the urgent need for inclusive, anatomy-based cancer care.
LGBTQ+ Cancer Disparities, Data Gaps, and the Clinical Stakes of Invisibility
By Mandi L. Pratt-Chapman, PhD
Expert commentary from Mandi L. Pratt-Chapman, PhD, on LGBTQ+ cancer disparities, SOGI data gaps, clinical trial inclusion, and the urgent need for inclusive, anatomy-based cancer care.
LGBTQ+ Cancer Disparities, Data Gaps, and the Clinical Stakes of Invisibility
By Mandi L. Pratt-Chapman, PhD
Expert commentary from Mandi L. Pratt-Chapman, PhD, on LGBTQ+ cancer disparities, SOGI data gaps, clinical trial inclusion, and the urgent need for inclusive, anatomy-based cancer care.
Zero Oncologists for 173,000 People: Confronting the Precision Oncology Crisis in Tribal Communities
By Monica Yellowhair, PhD
Dr. Monica Yellowhair examines the cancer care crisis in tribal communities, highlighting barriers to precision oncology access, Indigenous health equity, community navigation, and culturally grounded care.
Zero Oncologists for 173,000 People: Confronting the Precision Oncology Crisis in Tribal Communities
By Monica Yellowhair, PhD
Dr. Monica Yellowhair examines the cancer care crisis in tribal communities, highlighting barriers to precision oncology access, Indigenous health equity, community navigation, and culturally grounded care.
Zero Oncologists for 173,000 People: Confronting the Precision Oncology Crisis in Tribal Communities
By Monica Yellowhair, PhD
Dr. Monica Yellowhair examines the cancer care crisis in tribal communities, highlighting barriers to precision oncology access, Indigenous health equity, community navigation, and culturally grounded care.
Top 5 Takeaways from Dr. Paolo Tarantino on the Future of Antibody-Drug Conjugates in Solid Oncology
By The Cancer News Team
Key insights from Dr. Paolo Tarantino on how antibody-drug conjugates are transforming solid tumor treatment, moving from late-line therapy to frontline and curative-intent strategies.
Top 5 Takeaways from Dr. Paolo Tarantino on the Future of Antibody-Drug Conjugates in Solid Oncology
By The Cancer News Team
Key insights from Dr. Paolo Tarantino on how antibody-drug conjugates are transforming solid tumor treatment, moving from late-line therapy to frontline and curative-intent strategies.
Top 5 Takeaways from Dr. Paolo Tarantino on the Future of Antibody-Drug Conjugates in Solid Oncology
By The Cancer News Team
Key insights from Dr. Paolo Tarantino on how antibody-drug conjugates are transforming solid tumor treatment, moving from late-line therapy to frontline and curative-intent strategies.
Antibody-Drug Conjugates in Solid Tumors: From Magic Bullet to Standard of Care
By Paolo Tarantino, MD, PhD
Antibody-drug conjugates (ADCs) are transforming cancer care by delivering targeted chemotherapy with improved efficacy across multiple solid tumors, redefining treatment from late-line therapy to frontline standard.
Antibody-Drug Conjugates in Solid Tumors: From Magic Bullet to Standard of Care
By Paolo Tarantino, MD, PhD
Antibody-drug conjugates (ADCs) are transforming cancer care by delivering targeted chemotherapy with improved efficacy across multiple solid tumors, redefining treatment from late-line therapy to frontline standard.
Antibody-Drug Conjugates in Solid Tumors: From Magic Bullet to Standard of Care
By Paolo Tarantino, MD, PhD
Antibody-drug conjugates (ADCs) are transforming cancer care by delivering targeted chemotherapy with improved efficacy across multiple solid tumors, redefining treatment from late-line therapy to frontline standard.
Dr. Hina Khan on Closing the Gap: Lung Cancer Screening Disparities and the Fight for Equitable Low-Dose CT Access
By Hina Khan, MD
Lung cancer screening saves lives, yet disparities persist. Dr. Hina Khan explores barriers to low-dose CT access and community-driven solutions to improve early detection and equity.
Dr. Hina Khan on Closing the Gap: Lung Cancer Screening Disparities and the Fight for Equitable Low-Dose CT Access
By Hina Khan, MD
Lung cancer screening saves lives, yet disparities persist. Dr. Hina Khan explores barriers to low-dose CT access and community-driven solutions to improve early detection and equity.
Dr. Hina Khan on Closing the Gap: Lung Cancer Screening Disparities and the Fight for Equitable Low-Dose CT Access
By Hina Khan, MD
Lung cancer screening saves lives, yet disparities persist. Dr. Hina Khan explores barriers to low-dose CT access and community-driven solutions to improve early detection and equity.